Baxter Hlthcare Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for BAXTER HLTHCARE, and when can generic versions of BAXTER HLTHCARE drugs launch?
BAXTER HLTHCARE has two hundred and nine approved drugs.
There are fifteen US patents protecting BAXTER HLTHCARE drugs. There are three tentative approvals on BAXTER HLTHCARE drugs.
There are fifty-four patent family members on BAXTER HLTHCARE drugs in twenty countries and two hundred and seventy-seven supplementary protection certificates in fifteen countries.
Summary for Baxter Hlthcare
| International Patents: | 54 |
| US Patents: | 15 |
| Tradenames: | 321 |
| Ingredients: | 122 |
| NDAs: | 209 |
Drugs and US Patents for Baxter Hlthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER | calcium chloride; dextrose; lactic acid; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride | INJECTABLE;INJECTION | 021703-009 | Oct 25, 2006 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Baxter Hlthcare | POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% | potassium chloride; sodium chloride | INJECTABLE;INJECTION | 017648-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Baxter Hlthcare | DEXTROSE 70% IN PLASTIC CONTAINER | dextrose | INJECTABLE;INJECTION | 020047-003 | Jul 2, 1991 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Baxter Hlthcare | IFEX | ifosfamide | INJECTABLE;INJECTION | 019763-002 | Dec 30, 1988 | AP | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Baxter Hlthcare Corp | NOURESS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 212535-001 | Dec 13, 2019 | DISCN | Yes | No | 10,493,051 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Baxter Hlthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-002 | Nov 16, 2010 | 6,869,939 | ⤷ Try a Trial |
| Baxter Hlthcare | SUPRANE | desflurane | LIQUID;INHALATION | 020118-001 | Sep 18, 1992 | 5,617,906*PED | ⤷ Try a Trial |
| Baxter Hlthcare | EXTRANEAL | icodextrin | SOLUTION;INTRAPERITONEAL | 021321-001 | Dec 20, 2002 | 4,761,237 | ⤷ Try a Trial |
| Baxter Hlthcare | MESNEX | mesna | INJECTABLE;INTRAVENOUS | 019884-001 | Dec 30, 1988 | 4,220,660 | ⤷ Try a Trial |
| Baxter Hlthcare Corp | DOXIL (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 050718-002 | Jun 13, 2000 | 5,013,556 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Inhalation | 99.90% | ➤ Subscribe | 2008-09-11 |
| ➤ Subscribe | Injection | 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags | ➤ Subscribe | 2014-01-31 |
International Patents for Baxter Hlthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2003234285 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 03092590 | ⤷ Try a Trial |
| Brazil | 112022015170 | ⤷ Try a Trial |
| Japan | 2018052991 | ⤷ Try a Trial |
| Slovenia | 2402008 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Baxter Hlthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1224170 | SPC/GB15/018 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NINTEDANIB*, THE TAUTOMERS AND THE SALTS THEREOF, IN PARTICULAR NINTEDANIB AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY NINTEDANIB ESILATE. *NINTEDANIB IS 3-Z-(1-(4-N-((4-METHYL-PIPERAZIN-1-YL)-METHYLCARBONYL)-N-METHYL-AMINO)-A; REGISTERED: UK EU/1/14/954/001 20141125; UK EU/1/14/954/002 20141125; UK EU/1/14/954/003 20141125; UK EU/1/14/954/004 20141125 |
| 1718641 | SPC/GB12/028 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| 1870100 | 122012000047 | Germany | ⤷ Try a Trial | PRODUCT NAME: DABIGATRAN ETEXILAT MESILAT = 3-((2-((4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO)-METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO)-PROPIONSAEURE-ETHYLESTER-METHANSULFONAT; REGISTRATION NO/DATE: EU/1/08/442/001-008 20080318 |
| 0473687 | SPC/GB98/030 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204 |
| 2673237 | LUC00111 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
